

Table S1. Comparison of the baseline characteristics between the patients who developed HCC and those who did not.

Variable	Non-HCC (n=1855, 91.1%)	HCC (n=182, 8.9%)	p Value
Age (years)	49 (39–56)	55 (49–60)	<0.001
<40	464 (25.0)	4 (2.2)	
40–50	485 (26.1)	46 (25.3)	
50–60	600 (32.3)	81 (44.5)	<0.001
60–70	247 (13.3)	42 (23.1)	
≥70	59 (3.2)	9 (4.9)	
Male sex	1,063 (57.3)	116 (63.7)	0.940
Presence of cirrhosis	851 (45.9)	165 (90.7)	<0.001
HBeAg positivity	936 (50.5)	89 (48.9)	0.683
TDF use (vs. ETV)	1,030 (55.5)	90 (49.5)	0.116
Liver stiffness value [†] (kPa)	7.2 (5.2–11.8)	13.9 (9.8–21.9)	<0.001
Laboratory test results			
Platelet count ($\times 10^3/\mu\text{L}$)	172.5 (128.0–217.0)	122.0 (94.0–161.8)	<0.001
AST level (IU/L)	43.0 (27.0–83.0)	50.0 (37.0–80.0)	0.582
ALT level (IU/L)	48.0 (25.0–115.0)	47.5 (30.0–84.3)	<0.001
Total bilirubin level (mg/dL)	0.8 (0.6–1.1)	0.9 (0.7–1.4)	0.061
Serum albumin level (g/dL)	4.2 (3.9–4.4)	4.0 (3.5–4.2)	0.019
Prothrombin time level (INR)	1.00 (0.95–1.07)	1.04 (0.99–1.14)	<0.001
Alpha-fetoprotein level (ng/mL)	3.81 (2.51–7.24)	6.89 (4.41–13.66)	0.324

Values are expressed as *n* (%) or median (interquartile range). [†]Measured using transient elastography (FibroScan®, EchoSens, Paris, France). HCC, hepatocellular carcinoma; TDF, tenofovir disoproxyl fumarate; ETV, entecavir; HBeAg (+), positive for hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; HBV, hepatitis B virus.